Clearside Biomedical (NASDAQ:CLSD) Rating Reiterated by Chardan Capital

Clearside Biomedical (NASDAQ:CLSD)‘s stock had its “buy” rating reiterated by stock analysts at Chardan Capital in a research note issued to investors on Monday, Benzinga reports. They currently have a $6.00 price target on the stock. Chardan Capital’s target price would suggest a potential upside of 440.54% from the stock’s current price.

Several other equities analysts have also commented on CLSD. Oppenheimer started coverage on Clearside Biomedical in a research note on Tuesday, June 25th. They issued an “outperform” rating and a $5.00 target price for the company. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Clearside Biomedical in a research note on Tuesday, August 27th. Finally, Needham & Company LLC upped their price target on Clearside Biomedical from $4.00 to $6.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $5.17.

Clearside Biomedical Trading Down 6.7 %

Clearside Biomedical stock opened at $1.11 on Monday. The firm has a market capitalization of $82.95 million, a P/E ratio of -2.02 and a beta of 2.35. The stock has a fifty day moving average price of $1.15 and a 200 day moving average price of $1.22. Clearside Biomedical has a 52 week low of $0.65 and a 52 week high of $2.12.

Clearside Biomedical (NASDAQ:CLSD) last released its earnings results on Monday, August 12th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.04. The business had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.25 million. During the same quarter in the previous year, the company posted ($0.15) earnings per share. As a group, equities analysts predict that Clearside Biomedical will post -0.56 EPS for the current year.

Institutional Investors Weigh In On Clearside Biomedical

Several institutional investors and hedge funds have recently added to or reduced their stakes in CLSD. Assenagon Asset Management S.A. purchased a new stake in shares of Clearside Biomedical in the second quarter worth about $368,000. International Assets Investment Management LLC purchased a new stake in shares of Clearside Biomedical in the first quarter worth about $57,000. Vanguard Group Inc. boosted its position in shares of Clearside Biomedical by 14.5% in the first quarter. Vanguard Group Inc. now owns 2,490,796 shares of the company’s stock worth $3,811,000 after buying an additional 314,480 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Clearside Biomedical in the first quarter worth about $49,000. Finally, XTX Topco Ltd boosted its position in shares of Clearside Biomedical by 172.2% in the second quarter. XTX Topco Ltd now owns 54,313 shares of the company’s stock worth $71,000 after buying an additional 34,359 shares during the period. 18.75% of the stock is currently owned by institutional investors and hedge funds.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.